A Study of Donanemab (LY3002813) in Healthy Chinese Participants
Status:
Not yet recruiting
Trial end date:
2023-01-06
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to evaluate the safety and tolerability of donanemab
(LY3002813) when administered as single dose in healthy Chinese participants. The study will
also assess how fast donanemab gets into the blood stream and how long it takes the body to
remove it. The study is open to healthy participants. The study will last up to approximately
85 days.